Clinical Trial

GT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain Tumors

– Financing Led by Evidity Health Capital –  TEMPE, Ariz., Jan. 16, 2025 /PRNewswire/ -- GT Medical Technologies, Inc. (GT…

11 months ago

Kanavos Announces Industry First Knowledge Graph for Cannabis Patients

AI powered scientific evidence-based system developed in partnership with Graphwise and HomeLab SAN FRANCISCO, Jan. 16, 2025 /PRNewswire/ -- JP Morgan Healthcare Conference – Kanavos Inc, a trailblazer…

11 months ago

Caris Life Sciences Announces a Strategic Collaboration with Ontada® to Advance Oncology Research and the Adoption of Precision Medicine

The collaboration brings together Caris' extensive genomic data and molecular expertise with Ontada's robust clinical data and research capabilities to…

11 months ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency…

11 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE…

11 months ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) --…

11 months ago

Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development

Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable…

11 months ago

Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000…

11 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused…

11 months ago

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate…

11 months ago